TOP TEN perturbations for 1552952_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552952_at
Selected probe(set): 216544_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552952_at (216544_at) across 6672 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-0.77297306
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

Langerhans cell histiocytosis study 2 (multisystem) / Langerhans cell histiocytosis study 2 (multifocal)

Relative Expression (log2-ratio):0.73809624
Number of Samples:2 / 2
Experimental Langerhans cell histiocytosis study 2 (multisystem)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-0.70282507
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

granulomatosis with polyangiitis study 3 (orbital adipose tissue) / normal orbital adipose tissue

Relative Expression (log2-ratio):0.6661482
Number of Samples:9 / 22
Experimental granulomatosis with polyangiitis study 3 (orbital adipose tissue)
Orbital adipose tissue samples obtained from patients who suffered from granulomatosis with polyangiitis (GPA). Biopsies were formalin-fixed and paraffin-embedded.
Control normal orbital adipose tissue
Normal orbital adipose tissue samples. Samples were obtained from subjects with no history of orbital disease at the time of surgery such as fat typically excised and discarded as part of routine blepharoplasty or retrobulbar fat that is snared with the eye during enucleation. Biopsies were formalin-fixed and paraffin-embedded.

cadmium study 1 (brief) / untreated NPrEC cell sample

Relative Expression (log2-ratio):0.6498833
Number of Samples:2 / 2
Experimental cadmium study 1 (brief)
After 72h of starvation, NPrEC cells were briefly exposed to 2.5 uM CdCl2. ATC code:---
Control untreated NPrEC cell sample
After 72h of starvation, NPrEC cells were briefly exposed to complete medium without CdCl2.

tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-0.6458545
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):0.6439233
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

ibuprofen study 1 (150uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):0.5666237
Number of Samples:2 / 2
Experimental ibuprofen study 1 (150uM)
Hepatocytes treated with compound: ibuprofen (150uM; CHEMBL521) for 8 hours. ATC code:, , ,
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):-0.54246473
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.

ethanol study 2 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-0.53798485
Number of Samples:2 / 2
Experimental ethanol study 2 (10000uM)
Hepatocytes treated with compound: ethanol (10000uM; CHEMBL545) for 24 hours. ATC code:, ,
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.